Roche Elecsys Upgrades Go To Igen, But $486 Mil. In Penalties Are Vacated
This article was originally published in The Gray Sheet
Executive Summary
The path is clear for Igen to renegotiate a licensing and development deal with Roche Diagnostics, following a federal appeals court ruling July 9, enabling Igen to terminate its previous agreement